Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitorresistant recurrent ovarian cancer

Category Primary study
JournalJournal of Clinical Oncology
Year 2021
This article has no abstract
Epistemonikos ID: ea41afd96e7f63571ccdb3a1a7d1932537a8f8e1
First added on: Feb 13, 2025